Has the FDA Approved Apotex's Ruxolitinib Generic?
No, the FDA has not approved Apotex's generic version of ruxolitinib (the active ingredient in Jakafi) as of the latest available data. Apotex submitted an Abbreviated New Drug Application (ANDA) for ruxolitinib phosphate tablets (5 mg, 10 mg, 15 mg, 20 mg, and 25 mg), but it faces ongoing patent challenges from Incyte Corporation, the originator of Jakafi. The FDA cannot finalize approval until patent exclusivity issues are resolved.[1][2]
Why Is Apotex's ANDA Delayed?
Apotex's filing triggered a Paragraph IV certification, challenging Incyte's patents on Jakafi. Incyte sued Apotex in 2021 in the U.S. District Court for the District of Delaware, alleging infringement. The case remains active, with no final ruling granting Apotex a safe harbor for market entry. This Hatch-Waxman litigation typically delays generics by 30 months unless settled or dismissed.[1][3]
When Do Jakafi Patents Expire?
Key Jakafi patents expire between 2025 and 2029, including composition-of-matter (U.S. Patent No. 7,598,257, expiring February 2027) and method-of-use patents. Pediatric exclusivity could extend some to 2030. DrugPatentWatch tracks 28 Orange Book-listed patents; full generic entry likely post-2027 absent settlements.[2]
Which Companies Have FDA-Approved Ruxolitinib Generics?
No generics are FDA-approved for the full Jakafi strengths yet. Earlier approvals exist for topical ruxolitinib (Opzelura) generics, but oral tablets for conditions like myelofibrosis remain blocked. Incyte has authorized a single authorized generic via its own subsidiary.[2][4]
What Happens If Apotex Wins the Lawsuit?
A court victory for Apotex could lead to FDA approval within months, enabling 180-day exclusivity as the first Paragraph IV filer. However, other challengers (e.g., Sandoz, Dr. Reddy's) are in line, potentially splitting the market.[1][3]
Sources
[1]: FDA Paragraph IV Patent Settlements and Litigation
[2]: DrugPatentWatch: Ruxolitinib Patents
[3]: Delaware District Court Docket: Incyte v. Apotex
[4]: FDA Orange Book: Jakafi Approvals